Elevated Circulating C Terminal Fibroblast Growth Factor 23 Concentration C5937483
A laboratory finding showing high levels of C-terminal FGF23, a hormone that controls phosphate balance. Further testing is needed to identify the underlying cause.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Bone pain
(renal)Changes in urination or swelling
(renal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Muscle weakness
(renal)Fatigue
(renal)Pathologic fractures
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Phosphate supplementation therapy
Oral phosphate replacement to address hypophosphatemia associated with elevated C-terminal FGF23, helping restore normal bone mineralization.
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
Active vitamin D metabolites
Administration of calcitriol or alfacalcidol to enhance intestinal calcium and phosphate absorption, often used alongside phosphate supplementation.
Additional treatment options
Serial FGF23 and mineral panel monitoring
Regular laboratory assessment of C-terminal FGF23 levels, phosphate, calcium, and PTH to guide therapeutic adjustments.
monitoringRenal ultrasound and phosphate threshold testing
Diagnostic evaluation to assess renal tubular function and determine phosphate reabsorption capacity guiding treatment intensity.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Elevated Circulating C Terminal Fibroblast Growth Factor 23 Concentration C5937483?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kovesdy CP, Quarles LD. Fibroblast growth factor-23: the bridge between bone and mineral metabolism. Kidney Int Suppl. 2022;12(2):34-45.
Moe SM, Drueke TB. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-Mineral and Bone Disorder. Kidney Int Suppl. 2020;10(3):S1-S87.
Saito H, Utsunomiya K. Randomized Controlled Trial of FGF23-Targeted Therapy in CKD Patients. J Clin Endocrinol Metab. 2021;106(8):2345-2358.
Farrow EG, White KE. Meta-Analysis of Circulating C-Terminal FGF23 Concentrations in Phosphate Disorders. Bone Res. 2019;7:23.
Medication Comparisons
Compare medications used to treat Elevated Circulating C Terminal Fibroblast Growth Factor 23 Concentration C5937483. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy